Exon edited dystrophin rods in the hinge 3 region

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1824, Issue 10, 2012, Pages 1080-1089

  Sahni, Neha ^a   Mangat, Khushdeep ^a   Le Rumeur, Elisabeth ^b   Menhart, Nick ^a  

^a ILLINOIS INSTITUTE OF TECHNOLOGY   (United States)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Duchenne muscular dystrophy; Dystrophin; Exon skipping; Lipid; Stability

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DYSTROPHIN; LIPID; RECOMBINANT DYSTROPHIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DUCHENNE MUSCULAR DYSTROPHY; EXON; EXON 51 SKIPPING THERAPY; GENETIC ENGINEERING; HINGE REGION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN STABILITY; PROTEIN STRUCTURE; THERAPY;

CLONING, MOLECULAR; DYSTROPHIN; EXONS; HUMANS; PROTEIN DENATURATION; RETINAL ROD PHOTORECEPTOR CELLS;

EID: 84864068462     PISSN: 15709639     EISSN: 18781454     Source Type: Journal    
DOI: 10.1016/j.bbapap.2012.06.011     Document Type: Article

References (39)

1. A.J. van Essen, J.B.G.M. Verheij, J. Reefhuis, V. Fidler, J.H. Begeer, M. de Visser, and L.P. ten Kate Ch 3: the natural history of Duchenne muscular dystrophy; analysis of data from a Dutch survey and review of age related events vol. PhD 2004 University Medical Center Groningen Groningen, NL
2. R.T. Moxley III, S. Pandya, E. Ciafaloni, D.J. Fox, and K. Campbell Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management J. Child Neurol. 25 2010 1116 1129
3. A. Goyenvalle, A. Babbs, G.J. van Ommen, L. Garcia, and K.E. Davies Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: promising tool for DMD therapy Mol. Ther. 17 2009 1234 1240
4. Q.L. Lu, T. Yokota, S. Takeda, L. Garcia, F. Muntoni, and T. Partridge The status of exon skipping as a therapeutic approach to Duchenne muscular dystrophy Mol. Ther. 19 2011 9 15
5. A. Aartsma-Rus, I. Fokkema, J. Verschuuren, I. Ginjaar, J. van Deutekom, G.J. van Ommen, and J.T. den Dunnen Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations Hum. Mutat. 30 2009 293 299
6. I. Desguerre, C. Christov, M. Mayer, R. Zeller, H.M. Becane, S. Bastuji-Garin, F. Leturcq, C. Chiron, J. Chelly, and R.K. Gherardi Clinical heterogeneity of Duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up PLoS One 4 2009 e4347
7. R.W. Kaspar, H.D. Allen, W.C. Ray, C.E. Alvarez, J.T. Kissel, A. Pestronk, R.B. Weiss, K.M. Flanigan, J.R. Mendell, and F. Montanaro Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in Becker muscular dystrophy Circ. Cardiovasc. Genet. 2 2009 544 551
8. P.J. Taylor, G.A. Betts, S. Maroulis, C. Gilissen, R.L. Pedersen, D.R. Mowat, H.M. Johnston, and M.F. Buckley Dystrophin gene mutation location and the risk of cognitive impairment in Duchenne muscular dystrophy PLoS One 5 2010 e8803
9. C. Beroud, S. Tuffery-Giraud, M. Matsuo, D. Hamroun, V. Humbertclaude, N. Monnier, M.P. Moizard, M.A. Voelckel, L.M. Calemard, P. Boisseau, M. Blayau, C. Philippe, M. Cossee, M. Pages, F. Rivier, O. Danos, L. Garcia, and M. Claustres Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy Hum. Mutat. 28 2007 196 202
10. J.C. van Deutekom, A.A. Janson, I.B. Ginjaar, W.S. Frankhuizen, A. Aartsma-Rus, M. Bremmer-Bout, J.T. den Dunnen, K. Koop, A.J. van der Kooi, N.M. Goemans, S.J. de Kimpe, P.F. Ekhart, E.H. Venneker, G.J. Platenburg, J.J. Verschuuren, and G.J. van Ommen Local dystrophin restoration with antisense oligonucleotide PRO051 N. Engl. J. Med. 357 2007 2677 2686
11. D.M. Henderson, J.J. Belanto, B. Li, H. Heun-Johnson, and J.M. Ervasti Internal deletion compromises the stability of dystrophin Hum. Mol. Genet. 20 2011 2955 2963
12. A. Mirza, M. Sagathevan, N. Sahni, L. Choi, and N. Menhart A biophysical map of the dystrophin rod Biochim. Biophys. Acta 1804 2010 1796 1809
13. A. Mirza, and N. Menhart Stability of dystrophin STR fragments in relation to junction helicity Biochim. Biophys. Acta 1784 2008 1301 1309
14. S.C. Gill, and P.H. von Hippel Calculation of protein extinction coefficients from amino acid sequence data Anal. Biochem. 182 1989 319 326
15. J.M. Schurr Dynamic light scattering of biopolymers and biocolloids CRC Crit. Rev. Biochem. 4 1977 371 431
16. L. Saadat, L. Pittman, and N. Menhart Structural cooperativity in spectrin type repeats motifs of dystrophin Biochim. Biophys. Acta 1764 2006 943 954
17. E. Le Rumeur, Y. Fichou, S. Pottier, F. Gaboriau, C. Rondeau-Mouro, M. Vincent, J. Gallay, and A. Bondon Interaction of dystrophin rod domain with membrane phospholipids. Evidence of a close proximity between tryptophan residues and lipids J. Biol. Chem. 278 2003 5993 6001
18. S. Legardinier, C. Raguenes-Nicol, C. Tascon, C. Rocher, S. Hardy, J.F. Hubert, and E. Le Rumeur Mapping of the lipid-binding and stability properties of the central rod domain of human dystrophin J. Mol. Biol. 389 2009 546 558
19. N.E. Zhou, C.M. Kay, and R.S. Hodges Synthetic model proteins. Positional effects of interchain hydrophobic interactions on stability of two-stranded alpha-helical coiled-coils J. Biol. Chem. 267 1992 2664 2670
20. T.M. Cooper, and R.W. Woody The effect of conformation on the CD of interacting helices: a theoretical study of tropomyosin Biopolymers 30 1990 657 676
21. E.M. Landaw, and J.J. DiStefano III Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations Am. J. Physiol. 246 1984 R665 R677
22. N. Menhart Hybrid spectrin type repeats produced by exon-skipping in dystrophin Biochim. Biophys. Acta 1764 2006 993 999
23. S.Q. Harper, M.A. Hauser, C. DelloRusso, D. Duan, R.W. Crawford, S.F. Phelps, H.A. Harper, A.S. Robinson, J.F. Engelhardt, S.V. Brooks, and J.S. Chamberlain Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy Nat. Med. 8 2002 253 261
24. M. Koenig, and L.M. Kunkel Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility J. Biol. Chem. 265 1990 4560 4566
25. S. Legardinier, J.F. Hubert, O. Le Bihan, C. Tascon, C. Rocher, C. Raguenes-Nicol, A. Bondon, S. Hardy, and E. Le Rumeur Sub-domains of the dystrophin rod domain display contrasting lipid-binding and stability properties Biochim. Biophys. Acta 1784 2008 672 682
26. V. Vie, S. Legardinier, L. Chieze, O. Le Bihan, Y. Qin, J. Sarkis, J.F. Hubert, A. Renault, B. Desbat, and E. Le Rumeur Specific anchoring modes of two distinct dystrophin rod sub-domains interacting in phospholipid Langmuir films studied by atomic force microscopy and PM-IRRAS Biochim. Biophys. Acta 1798 1503 1511
27. V. Vie, S. Legardinier, L. Chieze, O. Le Bihan, Y. Qin, J. Sarkis, J.F. Hubert, A. Renault, B. Desbat, and E. Le Rumeur Specific anchoring modes of two distinct dystrophin rod sub-domains interacting in phospholipid Langmuir films studied by atomic force microscopy and PM-IRRAS Biochim. Biophys. Acta 1798 2010 1503 1511
28. A. Cornish-Bowden, and M.L. Cardenas Co-operativity in monomeric enzymes J. Theor. Biol. 124 1987 1 23
29. H. Qian Cooperativity and specificity in enzyme kinetics: a single-molecule time-based perspective Biophys. J. 95 2008 10 17
30. C. Ruszczak, A. Mirza, and N. Menhart Differential stabilities of alternative exon-skipped rod motifs of dystrophin Biochim. Biophys. Acta 1794 2009 921 928
31. S.J. Winder, T.J. Gibson, and J. Kendrick-Jones Dystrophin and utrophin: the missing links! FEBS Lett. 369 1995 27 33
32. E. Kahana, and W.B. Gratzer Minimum folding unit of dystrophin rod domain Biochemistry 34 1995 8110 8114
33. J. Sarkis, J.F. Hubert, B. Legrand, E. Robert, A. Cheron, J. Jardin, E. Hitti, E. Le Rumeur, and V. Vie Spectrin-like repeats 11-15 of human dystrophin show adaptations to a lipidic environment J. Biol. Chem. 286 2011 30481 30491
34. S.Q. Harper, R.W. Crawford, C. DelloRusso, and J.S. Chamberlain Spectrin-like repeats from dystrophin and alpha-actinin-2 are not functionally interchangeable Hum. Mol. Genet. 11 2002 1807 1815
35. K. Anthony, S. Cirak, S. Torelli, G. Tasca, L. Feng, V. Arechavala-Gomeza, A. Armaroli, M. Guglieri, C.S. Straathof, J.J. Verschuuren, A. Aartsma-Rus, P. Helderman-van den Enden, K. Bushby, V. Straub, C. Sewry, A. Ferlini, E. Ricci, J.E. Morgan, and F. Muntoni Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials Brain 134 2011 3547 3559
36. N.M. Goemans, M. Tulinius, J.T. van den Akker, B.E. Burm, P.F. Ekhart, N. Heuvelmans, T. Holling, A.A. Janson, G.J. Platenburg, J.A. Sipkens, J.M. Sitsen, A. Aartsma-Rus, G.J. van Ommen, G. Buyse, N. Darin, J.J. Verschuuren, G.V. Campion, S.J. de Kimpe, and J.C. van Deutekom Systemic administration of PRO051 in Duchenne's muscular dystrophy N. Engl. J. Med. 364 2011 1513 1522
37. M. Kinali, V. Arechavala-Gomeza, L. Feng, S. Cirak, D. Hunt, C. Adkin, M. Guglieri, E. Ashton, S. Abbs, P. Nihoyannopoulos, M.E. Garralda, M. Rutherford, C. McCulley, L. Popplewell, I.R. Graham, G. Dickson, M.J. Wood, D.J. Wells, S.D. Wilton, R. Kole, V. Straub, K. Bushby, C. Sewry, J.E. Morgan, and F. Muntoni Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study Lancet Neurol. 8 2009 918 928
38. S. Cirak, V. Arechavala-Gomeza, M. Guglieri, L. Feng, S. Torelli, K. Anthony, S. Abbs, M.E. Garralda, J. Bourke, D.J. Wells, G. Dickson, M.J. Wood, S.D. Wilton, V. Straub, R. Kole, S.B. Shrewsbury, C. Sewry, J.E. Morgan, K. Bushby, and F. Muntoni Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study Lancet 378 2011 595 605
39. S. Cirak, L. Feng, K. Anthony, V. Arechavala-Gomeza, S. Torelli, C. Sewry, J.E. Morgan, and F. Muntoni Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy Mol. Ther. 20 2012 462 467